PMID: 11920626Mar 29, 2002Paper

Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin

International Journal of Cancer. Journal International Du Cancer
Yasuhiro TadaSeiji Naito

Abstract

Overexpression of the P-glycoprotein/multidrug resistance 1 (MDR1) and multidrug resistance protein 1 (MRP1) gene is closely associated with the clinical outcome of various malignancies, and it is involved in responses to some anticancer chemotherapeutic agents including doxorubicin. Six human MRP subfamily members (MRP2-7) with structural similarities to MRP1 have been identified. Recently, the relationships between MRP2 and MRP3 expression levels of some cancer cells and drug sensitivity to doxorubicin have been reported, but the relationship between the clinical samples and drug sensitivity remains unclear. We determined the expressions of the MDR1, MRP1, MRP2 and MRP3 gene in bladder cancer during the clinical course and sought to learn whether the expression was correlated with drug responses to doxorubicin. Doxorubicin, used in chemotherapeutic treatment including intravesical and systemic chemotherapy, is an important anticancer agent for the treatment of bladder cancer. We used quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis for our study, and the sensitivity to doxorubicin in bladder cancer was determined using the in vitro succinate dehydrogenase inhibition test. Using 47 clinical sample...Continue Reading

References

May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·K UedaI Pastan
Mar 8, 1995·Biochemical and Biophysical Research Communications·V GekelerJ Beck
Jan 1, 1993·Annual Review of Biochemistry·M M Gottesman, I Pastan
Nov 1, 1995·Japanese Journal of Cancer Research : Gann·S NaitoJ Kumazawa
Jan 27, 1998·The Journal of Biological Chemistry·K ItoY Sugiyama
Jun 9, 1999·Proceedings of the National Academy of Sciences of the United States of America·M KoolP Borst

❮ Previous
Next ❯

Citations

Dec 4, 2010·Cancer Chemotherapy and Pharmacology·Osamu TakakuwaShigeki Sato
Dec 26, 2006·Pflügers Archiv : European journal of physiology·Eva Bakos, László Homolya
Mar 30, 2005·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Olivier FardelLea Payen
Jan 7, 2004·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Lauretta M S ChanBarry H Hirst
Sep 3, 2010·BMC Cancer·Chien-Tsun KuanDarell D Bigner
Jul 20, 2005·BMC Cancer·Federica Di NicolantonioIan A Cree
May 21, 2013·Proceedings of the National Academy of Sciences of the United States of America·Sabine KussJanine Mauzeroll
Feb 10, 2012·Expert Review of Anticancer Therapy·Ross M Drayton, James W F Catto
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Gabriele JedlitschkyHeyo K Kroemer
Mar 29, 2014·Drug Metabolism Reviews·Tereza Kunická, Pavel Souček
Jan 20, 2010·Drug Metabolism Reviews·Katalin JemnitzPeter Krajcsi
Mar 23, 2005·Liver International : Official Journal of the International Association for the Study of the Liver·Gernot ZollnerMichael Trauner
Feb 4, 2006·Life Sciences·Marilyn E Morris, Shuzhong Zhang
Jul 28, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S M GuichardD I Jodrell
Jan 31, 2015·Expert Opinion on Therapeutic Targets·Bishoy M FaltasJonathan E Rosenberg
Jan 9, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Annemarie GreifeJiri Hatina
May 20, 2014·Urologic Oncology·Annette HaydenSimon J Crabb
Aug 9, 2006·Journal of Translational Medicine·Blanca Segura-PachecoAlfonso Duenas-González
Jul 5, 2016·Biological & Pharmaceutical Bulletin·Hideyuki KushiharaTakaaki Kobayashi
Oct 1, 2004·Anti-cancer Drugs·Federica Di NicolantonioIan A Cree
Jan 19, 2006·Therapeutic Drug Monitoring·Yusuke MatsunagaHideyuki Saito
Jul 20, 2018·Cancer Medicine·Xiao-Guang ZhangFang-Min Chen
Mar 22, 2003·Expert Review of Anticancer Therapy·Tony Elliott, Tariq Sethi
Oct 8, 2003·The Oncologist·Gregory D LeonardSusan E Bates
Apr 2, 2020·Expert Review of Molecular Diagnostics·Charles Emmanuel Jebaraj WalterHatem Zayed
Jan 16, 2016·Oncotarget·Tetsu TomonariTetsuji Takayama
Nov 1, 2018·Journal of Cellular Biochemistry·Li WuZhi Peng Chen
Jan 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Shari A PilonWei-Zen Wei
Aug 21, 2020·Science Signaling·Masamichi HayashiMohammad O Hoque

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.